SCOTT SUMMERS, PhD portrait
  • Co-Director, Diabetes & Metabolism Research Center
  • Department Chair, Nutrition & Integrative Physiology
  • Professor, Nutrition & Integrative Physiology
  • Distinguished Professor, Nutrition & Integrative Physiology

Research Statement

Professor Summers had been a dominant voice advancing the idea that sphingolipids such as ceramide, which are produced by over-nutrition and inflammation, contribute to insulin resistance and metabolic disease. The opinion was initially controversial, and few publications other than his appeared on the topic. Nonetheless, the data were robust and the therapeutic potential of the pathway obvious. His work has appeared in the highest impact journals (e.g. Nature Medicine, Cell Metabolism, Journal of Clinical Investigation and others) and have been cited over 8000 times. He has given over 100 presentations in at least 20 different countries, including keynote talks in Japan, Finland and the USA, and received over 10 million dollars in research grant support. His work has influenced the directions of new and established researchers and the number of publications containing the words ceramide and insulin has risen exponentially. His current group continues to explore the therapeutic potential of the pathway with an eye towards developing new therapies to treat diabetes and metabolic disease.

Presentations

  • (2017) Brigham Young University, Provo, UT. Presentation, Presented, 09/2017.
  • (2016) Molecular Medicine of Sphingolipids, French Lick, IN. Presentation, Presented, 09/2016.
  • (2016) Danish Diabetes Academy, Denmark. Presentation, Presented, 09/2016.
  • (2015) Pfizer Inc., Cambridge, MA. Presentation, Presented, 12/2015.
  • (2015) Cornell University Medical School, New York. Presentation, Presented, 12/2015.
  • (2015) University of Utah, Salt Lake City, UT. Presentation, Presented, 12/2015.
  • (2015) University of South Australia, Adelaide, Australia. Presentation, Presented, 11/2015.
  • (2015) Janssen Pharmaceuticals, Palo Alto, CA. Presentation, Presented, 10/2015.
  • (2015) Monash University, Melbourne, VIC. Presentation, Presented, 09/2015.
  • (2015) Mississippi State University, Starkville, MS. Presentation, Presented, 02/2015.
  • (2008) Diabetes Center, Albert Einstein College of Medicine, New York, NY. Other, Presented, 03/17/2008.
  • (2008) Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana. Other, Presented, 01/17/2008.
  • (2007) Obesity and Nutrition Research Center, University of Pittsburgh. Pittsburgh, Pennsylvania. Other, Presented, 12/13/2007.
  • (2007) Mexican Society of Endocrinology, Aguascalientes City, Mexico. Other, Presented, 11/28/2007.
  • (2007) Division of Preventive Medicine & Nutrition, Columbia University School of Medicine, New York, NY. Other, Presented, 09/15/2007.
  • (2007) Department of Human Nutrition, Foods, and Exercise, Virginia Tech, Blacksburg, Virginia. Other, Presented, 09/13/2007.
  • (2007) Astra Zeneca, Gothenburg, Sweden. Other, Presented, 09/01/2007.
  • (2007) PhD School of Molecular Metabolism, Odense, Denmark. Other, Presented, 09/01/2007.
  • (2007) FASEB Summer Conference, Glucose Transporter Biology, Snowmass, Colorado. Other, Presented, 08/06/2007.
  • (2007) Genzyme, Boston, Massachussetts. Other, Presented, 07/22/2007.
  • (2007) Metabolic Diseases Drug Discovery Summit, La Jolla, CA. Other, Presented, 07/06/2007.
  • (2007) American Diabetes Association, Chicago, Illinois. Other, Presented, 06/23/2007.
  • (2007) International Symposium on Insulin Receptors and Insulin Action, Stockholm, Sweden. Other, Presented, 05/04/2007.
  • (2007) Stock Obesity Conference, Bangkok, Thailand. Other, Presented, 03/30/2007.
  • (2007) Department of Cell and Molecular Biology, Penn State College of Medicine, Hershey, Pennsylvania. Other, Presented, 02/15/2007.
  • (2006) Center for Diabetes Research, Indiana University, Indianapolis, IN. Other, Presented, 12/15/2006.
  • (2006) Nestle Nutrition Conference, Mexico City, Mexico. Other, Presented, 11/09/2006.
  • (2006) Amgen-San Francisco, San Francisco, California. Other, Presented, 10/13/2006.
  • (2006) Gordon Conference, Glycolipid and Sphingolipid Biology, Ventura, CA. Other, Presented, 01/05/2006.
  • (2005) Eli Lilly Pharmaceuticals, Indianapolis, Indiana. Other, Presented, 05/13/2005.
  • (2005) Charleston Ceramide Conference, Charleston, South Carolina. Other, Presented, 03/11/2005.
  • (2005) Department of Chemistry, Colorado State University - Pueblo, Pueblo, Colorado. Other, Presented, 03/07/2005.
  • (2004) Eli Lilly Pharmaceuticals, Indianapolis, Indiana. Other, Presented, 09/05/2004.
  • (2003) Department of Biochemistry, University of Utah, Salt Lake City, Utah. Other, Presented, 09/01/2003.
  • (2003) FASEB Summer Conference, Glucose Transporter Biology, Snowmass, Colorado. Other, Presented, 08/04/2003.
  • (2003) Charleston Ceramide Conference, Como, Italy. Other, Presented, 06/12/2003.
  • (2002) REU Summer Research Program, Colorado State University. Other, Presented, 08/07/2002.
  • (2002) Department of Animal Sciences, Colorado State University, Fort Collins, CO. Other, Presented, 03/01/2002.
  • (2002) Department of Biology, University of Colorado Health Sciences Center, Denver, Colorado. Other, Presented, 03/01/2002.
  • (2002) Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina. Other, Presented, 02/25/2002.
  • (2002) Center for Nutrition Research, University of Colorado Health Sciences Center. Other, Presented, 02/15/2002.
  • (2002) Department of Pharmacology and Toxicology, University of Kansas. Other, Presented, 02/02/2002.
  • (2002) Department of Pharmacology and Cancer Biology, Duke University Medical School, Durham, North Carolina. Other, Presented, 02/01/2002.
  • (2002) Gordon Conference, Glycolipid and Sphingolipid Biology, Ventura, California. Other, Presented, 01/10/2002.
  • (2001) First Bi-Annual Charleston Ceramide Conference, Charleston, South Carolina. Other, Presented, 11/11/2001.
  • (2001) Clinical Scholar's Meeting, Aspen, Colorado. Other, Presented, 09/06/2001.
  • (2001) Department of Pathology, Colorado State University. Other, Presented, 04/01/2001.
  • (2000) Department of Endocrinology, University of Colorado Health Sciences Center. Other, Presented, 12/01/2000.
  • (2000) Department of Cell and Molecular Biology, University of Wyoming, September, 1999. Other, Presented, 09/01/2000.
  • (1999) Center for Nutrition Research, University of Colorado Health Sciences Center. Other, Presented, 09/01/1999.
  • (1999) FASEB Summer Conference on Glucose Transporter Biology, Snowmass, Colorado. Other, Presented, 07/02/1999.
  • (1999) The Picower Institute for Medical Research, Long Island, NY. Other, Presented, 06/15/1999.
  • (1998) Department of Biology, University of Texas, Austin, TX. Other, Presented, 11/01/1998.
  • (1998) Mid-Atlantic Diabetes Research Symposium, NIH, Bethesda, MD. Other, Presented, 09/12/1998.
  • (1997) Mid-Atlantic Diabetes Research Symposium, NIH, Bethesda, Maryland. Other, Presented, 04/19/1997.

Languages

  • English, fluent.

Geographical Regions of Interest

  • South-Eastern Asia
    USA, Southeast Asia, Pacific Rim.

Publications

  • Poss AM, Holland WL, Summers (2019). Risky Lipids. Refining the Ceramide Score that Measures Cardiovascular Health. European Heart Journal. Accepted, 02/01/2019.
  • Summers SA, Chaurasia B, Holland WL (2019) Metabolic Messengers: Ceramides. Nature Metabolism (in press). Accepted, 01/2019.
  • Funai K, Summers SA, Rutter JA (2019 Reign in the Membrane: How common lipids govern mitochondrial function. Current Opinion in Cell Biology (in press). Published, 01/2019.
  • Poss AM, Holland WL, Summers SA (2019) Risky Lipids. Refining the Ceramide Score that Measures Cardiovascular Health. European Heart Journal (in press). Published, 01/2019.
  • Verkerke ARP, Ferrara PJ, Lin C-T, Johnson JM, Ryan TE, Maschek JA, Eshima H, Paran CW, Laing BT, Siripoksup P, Tippetts TS, Wentzler EJ, Huang H, Spangenburg EE, Brault JJ, Villanueva CJ, Summers SA, Holland WL, Cox JE, Vance DE, Neufer PD. and Funai K (2019) Phospholipid methylation regulates muscle metabolic rate through Ca2+ transport efficiency. Nature Metabolism (in press). Published, 01/2019.
  • Karanth S, Chaurasia B, Bowman F, Tippetts T, Holland WL, Summers SA, and Schlegel A (2019) FOXN3 controls liver glucose metabolism by regulating gluconeogenic substrate selection (in press). Published, 01/2019.
  • Chaurasia B, Tippetts T, Monibas R, Liu J. Li Y, Wang L, Wilkerson J, Sweeney C.R, Pereira R, Sumida D, Maschek J. A., Cox J, Kaddai V, Lancaster G, Siddique M, Poss A, Pearson M, Satapati S, Zhou H, McLaren D, Previs S, Chen Y, Qian Y, Petrov A, Wu M, Shen X, Yao J, Nunes C, Howard A, Wang L, Erion M, Rutter J, Holland W, Kelley D, and Summers S. A. (2019) Targeting a Ceramide Double Bond Improves Insulin Resistance and Hepatic Steatosis. Science 365, 386-392. Published, 01/2019.
  • Kiser PD, Kolesnikov AV, Kiser JZ, Dong Z, Chaurasia B, Wang L, Summers SA, Hoang T, Blackshaw S, Peachey NS, Kefalov VJ, Palczewski K. (2019) Conditional deletion of Des1 in the mouse retina does not impair the visual cycle in cones. FASEB J. 33(4), 5782-5792. Published, 01/2019.
  • Wilkerson JL, Summers SA, and Holland WL (2019) Listen to your heart when ceramide's calling for higher glucose. EBioMedicine (in press). Accepted, 01/2019.
  • Holland WL and Summers SA (2018) Strong Heart, Low Ceramides. Diabetes 67(8), 1457-1460. Published, 01/2018.
  • Chaurasia B, Holland WL, Summers SA (2018) Does this Schlank make me look fat. Trends in Endocrinology and Metabolism 29(9), 597-599. Published, 01/2018.
  • de Carvalho LP, Tan SH, Ow GS, Tang Z, Ching J, Kovalik JP, Poh SC, Chin CT, Richards AM, Martinez EC, Troughton RW, Fong AY, Yan BP, Seneviratna A, Sorokin V, Summers SA, Kuznetsov VA, Chan MY. (2018) Plasma Ceramides as Prognostic Biomarkers and Their Arterial and Myocardial Tissue Correlates in Acute Myocardial Infarction. JACC Basic and Translational Science 3(2), 163-175. Published, 01/2018.
  • Tippetts TS, Holland WL, and Summers SA (2018) The Ceramide Ratio: A Predictor of Cardiometabolic Risk. Journal of Lipid Research 59(9), 1549-1550. Published, 01/2018.
  • An J, Wang LP, Patnode ML, Ridaura VK, Haldeman JM, Stevens RD, Ilkayeva O, Bain JR, Muehlbauer MJ, Glynn E, Thomas S, Muoio D, Summers SA, Vath JE, Hughes TE, Gordon JI, and Newgard CB (2018) Physiological mechanisms of sustained fumagillin-induced weight loss. JCI Insight 3(5). Published, 01/2018.
  • Summer Sa (2018). Could ceramides become the new cholesterol? . Cell Metabolism. Accepted, 01/2018.
  • Cai J, Pires KM, Ferhat M, Chaurasia B, Buffolo MA, Smalling R, Sargsyan A, Atkinson DA, Summers SA, Graham TE, and Boudina S (2018) Ablation of autophagy machinery in mature adipocytes induces insulin resistance and reveals new roles for lipid peroxides and Nrf2 signaling in adipose-liver crosstalk. Cell Reports 25(7), 1708-1717. Published, 01/2018.
  • Meikle PJ & Summers SA (2017). Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nature Reviews in Endocrinology and Metabolism. Vol. 13(2), 79-91. Published, 01/2017.
  • Liu JJ, Ghosh S, Kovalik JP , Ching J, Choi HW, Tavintharan S, Ong CN, Sum CF, Summers SA, Tai ES & Lim SC (2017). Profiling of plasma metabolite suggests altered mitochondrial fuel usage and remodeling of sphingolipid metabolism in individuals with type 2 diabetes and kidney disease. Kidney International Reports. Vol. 2(3), 470-480. Published, 01/2017.
  • Chaurasia, B, Kaddai, VA, Lancaster, GI, Toh Ee Shiow, SA, Sugii, S, and Summers, SA. Adipocyte Ceramides Regulate Subcutaneous Adipose Browning, Inflammation, and Metabolism, Cell Metabolism (2016), http://dx.doi.org/10.1016/j.cmet.2016.10.002. Published, 11/2016.
    http://www.sciencedirect.com/science/article/pii/S...
  • Meikle P & Summers SA. Sphingolipids and Phospholipids in Insulin Resistance and Related Metabolic Disorders, Nature Reviews Endocrinology (2016). Published, 10/2016.
  • Summers SA & Goodpaster BH (2016). Rebuttal from Scott A. Summers and Bret H. Goodpaster. The Journal of physiology. Vol. 594, 3175-6. Published, 06/01/2016.
  • Summers SA & Goodpaster BH (2016). CrossTalk proposal: Intramyocellular ceramide accumulation does modulate insulin resistance. The Journal of physiology. Vol. 594, 3167-70. Published, 06/01/2016.
  • Lee MH, Goralczyk AG, Kriszt R, Ang XM, Badowski , Li Y, Summers SA , Toh S-A, Yassin MS, Shabbir A, Sheppard A & Raghunath M (2016). ECM microenvironment unlocks down adipogenic potential of adult human bone marrow-derived MSCs. Scientific Reports 6. Vol. 21173. Published, 01/2016.
  • Park M, Kaddai V, Ching J, Fridianto KT, Sieli RJ, Sugii S & Summers SA (2016). Role for Ceramides, but NOT Sphingomyelins, as antagonists of insulin signaling and mitochondrial metabolism in C2C12 myotubes. Journal of Biological Chemistry. Vol. 291, 23978-23988. Published, 01/2016.
  • Goodpaster B & Summers SA (2016). CrossTalk Proposal: Intramyocellular ceramides do not cause insulin resistance. Journal of Physiology. Vol. 594(12)316703170. Published, 01/2016.
  • Goodpaster B & Summers SA (2016). Rebuttal to CrossTalk Proposal: Intramyocellular ceramides do no cause insulin resistance. Journal of Physiology. Vol. 594, 3167-3170. Published, 01/2016.
  • Bharath LP, Ruan T, Li Y, Ravindran A, Wan X, Nhan JK, Walker ML, Deeter L, Goodrich R, Johnson E, Munday D, Mueller R, Kunz D, Jones D, Reese V, Summers SA, Babu PV, Holland WL, Zhang QJ, Abel ED & Symons JD (2015). Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo. Diabetes. Vol. 64, 3914-26. Published, 10/01/2015.
  • Chaurasia B & Summers SA (2015). Ceramides - Lipotoxic Inducers of Metabolic Disorders. Trends in endocrinology and metabolism: TEM. Vol. 26, 538-50. Published, 09/01/2015.
  • Summers SA (2015). The ART of Lowering Ceramides. (pp. 195-6). Vol. 22. Cell metabolism. Published, 08/01/2015.
  • Teh JT, Zhu WL, Ilkayeva OR, Li Y, Gooding J, Casey PJ, Summers SA, Newgard CB & Wang M (2015). Isoprenylcysteine carboxylmethyltransferase regulates mitochondrial respiration and cancer cell metabolism. Oncogene. Vol. 34, 3296-304. Published, 06/01/2015.
  • Siddique MM, Li Y, Chaurasia B, Kaddai VA & Summers SA (2015). Dihydroceramides: From Bit Players to Lead Actors. The Journal of biological chemistry. Vol. 290, 15371-9. Published, 06/01/2015.
  • Barbarroja N, Rodriguez-Cuenca S, Nygren H, Camargo A, Pirraco A, Relat J, Cuadrado I, Pellegrinelli V, Medina-Gomez G, Lopez-Pedrera C, Tinahones FJ, Symons JD, Summers SA, Oresic M & Vidal-Puig A (2015). Increased dihydroceramide/ceramide ratio mediated by defective expression of degs1 impairs adipocyte differentiation and function. Diabetes. Vol. 64, 1180-92. Published, 03/01/2015.
  • Goodspeed D, Seferovic MD, Holland W, Mcknight RA, Summers SA, Branch DW, Lane RH & Aagaard KM (2015). Essential nutrient supplementation prevents heritable metabolic disease in multigenerational intrauterine growth-restricted rats. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. Vol. 29, 807-19. Published, 03/01/2015.
  • Raichur S, Wang ST, Chan PW, Li Y, Ching J, Chaurasia B, Chaurasia B, Dogra S, Öhman MK, Takeda K, Sugii S, Pewzner-Jung Y, Futerman AH & Summers SA (2014). CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell metabolism. Vol. 20, 687-95. Published, 10/01/2014.
  • Sinha RA, Farah BL, Singh BK, Siddique MM, Li Y, Wu Y, Ilkayeva OR, Gooding J, Ching J, Zhou J, Martinez L, Xie S, Bay BH, Summers SA, Newgard CB & Yen PM (2014). Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology (Baltimore, Md.). Vol. 59, 1366-80. Published, 03/01/2014.
  • Chavez JA, Siddique MM, Wang ST, Ching J, Shayman JA & Summers SA (2014). Ceramides and glucosylceramides are independent antagonists of insulin signaling. The Journal of biological chemistry. Vol. 289, 723-34. Published, 01/01/2014.
  • Chua EC, Shui G, Lee IT, Lau P, Tan LC, Yeo SC, Lam BD, Bulchand S, Summers SA, Puvanendran K, Rozen SG, Wenk MR & Gooley JJ (2013). Extensive diversity in circadian regulation of plasma lipids and evidence for different circadian metabolic phenotypes in humans. Proceedings of the National Academy of Sciences of the United States of America. Vol. 110, 14468-73. Published, 08/01/2013.
  • Siddique MM, Li Y, Wang L, Ching J, Mal M, Ilkayeva O, Wu YJ, Bay BH & Summers SA (2013). Ablation of dihydroceramide desaturase 1, a therapeutic target for the treatment of metabolic diseases, simultaneously stimulates anabolic and catabolic signaling. Molecular and cellular biology. Vol. 33, 2353-69. Published, 05/01/2013.
  • Siddique MM, Bikman BT, Wang L, Ying L, Reinhardt E, Shui G, Wenk MR & Summers SA (2012). Ablation of dihydroceramide desaturase confers resistance to etoposide-induced apoptosis in vitro. PloS one. Vol. 7, e44042. Published, 09/01/2012.
  • Sinha RA, You SH, Zhou J, Siddique MM, Bay BH, Zhu X, Privalsky ML, Cheng SY, Stevens RD, Summers SA, Newgard CB, Lazar MA & Yen PM (2012). Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. The Journal of clinical investigation. Vol. 122, 2428-38. Published, 07/01/2012.
  • Zhang QJ, Holland WL, Wilson L, Tanner JM, Kearns D, Cahoon JM, Pettey D, Losee J, Duncan B, Gale D, Kowalski CA, Deeter N, Nichols A, Deesing M, Arrant C, Ruan T, Boehme C, McCamey DR, Rou J, Ambal K, Narra KK, Summers SA, Abel ED & Symons JD (2012). Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes. Vol. 61, 1848-59. Published, 06/01/2012.
  • Chavez JA & Summers SA (2012). A ceramide-centric view of insulin resistance. Cell metabolism. Vol. 15, 585-94. Published, 05/01/2012.
  • Bikman BT, Guan Y, Shui G, Siddique MM, Holland WL, Kim JY, Fabriàs G, Wenk MR & Summers SA (2012). Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis. The Journal of biological chemistry. Vol. 287, 17426-37. Published, 05/01/2012.
  • Bikman BT & Summers SA (2011). Ceramides as modulators of cellular and whole-body metabolism. The Journal of clinical investigation. Vol. 121, 4222-30. Published, 11/01/2011.
  • Bikman BT & Summers SA (2011). Sphingolipids and hepatic steatosis. Advances in experimental medicine and biology. Vol. 721, 87-97. Published, 09/01/2011.
  • Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, Wenk MR, Pagliassotti MJ, Scherer PE & Summers SA (2011). Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. The Journal of clinical investigation. Vol. 121, 1858-70. Published, 05/01/2011.
  • Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA & Scherer PE (2011). Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nature medicine. Vol. 17, 55-63. Published, 01/01/2011.
  • Summers SA (2010). Sphingolipids and insulin resistance: the five Ws. Current opinion in lipidology. Vol. 21, 128-35. Published, 07/01/2010.
  • Chavez JA & Summers SA (2010). Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochimica et biophysica acta. Vol. 1801, 252-65. Published, 02/01/2010.
  • Fujii N, Ho RC, Manabe Y, Jessen N, Toyoda T, Holland WL, Summers SA, Hirshman MF & Goodyear LJ (2008). Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice. Diabetes. Vol. 57, 2958-66. Published, 10/01/2008.
  • Holland WL & Summers SA (2008). Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocrine reviews. Vol. 29, 381-402. Published, 06/01/2008.
  • Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL & Summers SA (2007). Lipid mediators of insulin resistance. Nutrition reviews. Vol. 65, S39-46. Published, 07/01/2007.
  • Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ & Summers SA (2007). Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell metabolism. Vol. 5, 167-79. Published, 03/01/2007.
  • Arbiser JL, Kau T, Konar M, Narra K, Ramchandran R, Summers SA, Vlahos CJ, Ye K, Perry BN, Matter W, Fischl A, Cook J, Silver PA, Bain J, Cohen P, Whitmire D, Furness S, Govindarajan B & Bowen JP (2007). Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. Blood. Vol. 109, 560-5. Published, 01/01/2007.
  • Summers SA (2006). Ceramides in insulin resistance and lipotoxicity. Progress in lipid research. Vol. 45, 42-72. Published, 02/01/2006.
  • Safadi-Chamberlain F, Wang LP, Payne SG, Lim CU, Stratford S, Chavez JA, Fox MH, Spiegel S & Summers SA (2005). Effect of a membrane-targeted sphingosine kinase 1 on cell proliferation and survival. The Biochemical journal. Vol. 388, 827-34. Published, 06/01/2005.
  • Chavez JA, Holland WL, Bär J, Sandhoff K & Summers SA (2005). Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. The Journal of biological chemistry. Vol. 280, 20148-53. Published, 05/01/2005.
  • Summers SA & Nelson DH (2005). A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. Diabetes. Vol. 54, 591-602. Published, 02/01/2005.
  • Florant GL, Porst H, Peiffer A, Hudachek SF, Pittman C, Summers SA, Rajala MW & Scherer PE (2004). Fat-cell mass, serum leptin and adiponectin changes during weight gain and loss in yellow-bellied marmots (Marmota flaviventris). (pp. 633-9). Vol. 174. Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology. Published, 11/01/2004.
  • Stratford S, Hoehn KL, Liu F & Summers SA (2004). Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. The Journal of biological chemistry. Vol. 279, 36608-15. Published, 08/01/2004.
  • Summers SA, Matijevic A & Almond MK (2004). Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia. (pp. 2137-9). Vol. 19. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. Published, 07/01/2004.
  • Hoehn KL, Hudachek SF, Summers SA & Florant GL (2004). Seasonal, tissue-specific regulation of Akt/protein kinase B and glycogen synthase in hibernators. American journal of physiology. Regulatory, integrative and comparative physiology. Vol. 286, R498-504. Published, 02/01/2004.
  • Chavez JA & Summers SA (2003). Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. (pp. 101-9). Vol. 419. Archives of biochemistry and biophysics. Published, 10/01/2003.
  • Hoehn KL & Summers SA (2003). Assaying AKT/protein kinase B activity. Methods in molecular medicine. Vol. 83, 137-44. Published, 03/01/2003.
  • Wang LP & Summers SA (2003). Measuring insulin-stimulated phosphatidyl-inositol 3-kinase activity. Methods in molecular medicine. Vol. 83, 127-36. Published, 03/01/2003.
  • Chavez JA, Knotts TA, Wang LP, Li G, Dobrowsky RT, Florant GL & Summers SA (2003). A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. The Journal of biological chemistry. Vol. 278, 10297-303. Published, 03/01/2003.
  • Ho RC, Davy KP, Hickey MS, Summers SA & Melby CL (2002). Behavioral, metabolic, and molecular correlates of lower insulin sensitivity in Mexican-Americans. American journal of physiology. Endocrinology and metabolism. Vol. 283, E799-808. Published, 09/01/2002.
  • Stratford S, DeWald DB & Summers SA (2001). Ceramide dissociates 3'-phosphoinositide production from pleckstrin homology domain translocation. The Biochemical journal. Vol. 354, 359-68. Published, 02/01/2001.
  • Summers SA, Whiteman EL & Birnbaum MJ (2000). Insulin signaling in the adipocyte. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. Vol. 24 Suppl 4, S67-70. Published, 12/01/2000.
  • Summers SA, Yin VP, Whiteman EL, Garza LA, Cho H, Tuttle RL & Birnbaum MJ (2000). Signaling pathways mediating insulin-stimulated glucose transport. Annals of the New York Academy of Sciences. Vol. 892, 169-86. Published, 06/01/2000.
  • Hausdorff SF, Fingar DC, Morioka K, Garza LA, Whiteman EL, Summers SA & Birnbaum MJ (1999). Identification of wortmannin-sensitive targets in 3T3-L1 adipocytes. DissociationoOf insulin-stimulated glucose uptake and glut4 translocation. The Journal of biological chemistry. Vol. 274, 24677-84. Published, 09/01/1999.
  • Cass LA, Summers SA, Prendergast GV, Backer JM, Birnbaum MJ & Meinkoth JL (1999). Protein kinase A-dependent and -independent signaling pathways contribute to cyclic AMP-stimulated proliferation. Molecular and cellular biology. Vol. 19, 5882-91. Published, 09/01/1999.
  • Summers SA, Whiteman EL, Cho H, Lipfert L & Birnbaum MJ (1999). Differentiation-dependent suppression of platelet-derived growth factor signaling in cultured adipocytes. The Journal of biological chemistry. Vol. 274, 23858-67. Published, 09/01/1999.
  • Summers SA, Kao AW, Kohn AD, Backus GS, Roth RA, Pessin JE & Birnbaum MJ (1999). The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism. The Journal of biological chemistry. Vol. 274, 17934-40. Published, 07/01/1999.
  • Kallen CB, Billheimer JT, Summers SA, Stayrook SE, Lewis M & Strauss JF (1998). Steroidogenic acute regulatory protein (StAR) is a sterol transfer protein. The Journal of biological chemistry. Vol. 273, 26285-8. Published, 11/01/1998.
  • Summers SA, Garza LA, Zhou H & Birnbaum MJ (1998). Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Molecular and cellular biology. Vol. 18, 5457-64. Published, 09/01/1998.
  • Zhou H, Summers SA, Birnbaum MJ & Pittman RN (1998). Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. The Journal of biological chemistry. Vol. 273, 16568-75. Published, 08/01/1998.
  • Summers SA, Lipfert L & Birnbaum MJ (1998). Polyoma middle T antigen activates the Ser/Thr kinase Akt in a PI3-kinase-dependent manner. Biochemical and biophysical research communications. Vol. 246, 76-81. Published, 06/01/1998.
  • Kohn AD, Barthel A, Kovacina KS, Boge A, Wallach B, Summers SA, Birnbaum MJ, Scott PH, Lawrence JC & Roth RA (1998). Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. The Journal of biological chemistry. Vol. 273, 11937-43. Published, 06/01/1998.
  • Summers SA & Birnbaum MJ (1998). A role for the serine/threonine kinase, Akt, in insulin-stimulated glucose uptake. Biochemical Society transactions. Vol. 25, 981-8. Published, 01/01/1998.
  • Summers SA, Guebert BA & Shanahan MF (1997). Polyphosphoinositide inclusion in artificial lipid bilayer vesicles promotes divalent cation-dependent membrane fusion. (pp. 3199-206). Vol. 71. Biophysical journal. Published, 04/01/1997.
  • Kohn AD, Summers SA, Birnbaum MJ & Roth RA (1997). Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. The Journal of biological chemistry. Vol. 271, 31372-8. Published, 01/01/1997.
  • Wandel S, Schurmann A, Becker W, Summers SA, Shanahan MF & Joost HG (1996). Mutation of two conserved arginine residues in the glucose transporter GLUT4 supresses transport activity, but not glucose-inhibitable binding of inhibitory ligands. Naunyn-Schmiedeberg's archives of pharmacology. Vol. 353, 36-41. Published, 11/01/1996.
  • Wandel S, Buchs A, Schürmann A, Summers SA, Powers AC, Shanahan MF & Joost HG (1996). Glucose transport activity and ligand binding (cytochalasin B, IAPS-forskolin) of chimeric constructs of GLUT2 and GLUT4 expressed in COS-7-cells. Biochimica et biophysica acta. Vol. 1284, 56-62. Published, 11/01/1996.
  • Wandel S, Schürmann A, Becker W, Summers SA, Shanahan MF & Joost HG (1994). Substitution of conserved tyrosine residues in helix 4 (Y143) and 7 (Y293) affects the activity, but not IAPS-forskolin binding, of the glucose transporter GLUT4. FEBS letters. Vol. 348, 114-8. Published, 08/01/1994.